Melatonin attenuates gentamicin-induced nephrotoxicity and oxidative stress in rats

College of Veterinary Medicine, Chonnam National University, Gwangju, 500-757, Republic of Korea.
Archives of Toxicology (Impact Factor: 5.98). 04/2012; 86(10):1527-36. DOI: 10.1007/s00204-012-0849-8
Source: PubMed


The present study investigated the protective effects of melatonin (MT) against gentamicin (GM)-induced nephrotoxicity and oxidative stress in rats. We also investigated the effects of MT on induction of apoptotic cell death and its potential mechanisms in renal tissues in response to GM treatment. The following four experimental groups were evaluated: (1) vehicle control, (2) MT (15 mg/kg/day), (3) GM (100 mg/kg/day), and (4) GM&MT. GM caused severe nephrotoxicity as evidenced by increased serum blood urea nitrogen and creatinine levels, increased renal tubular cell apoptosis, and increased Bcl2-associated X protein and cleaved caspase-3 protein expression. Additionally, GM treatment caused an increase in levels of inducible nitric oxide synthase (iNOS) and nuclear factor-kappa B (NF-κB) protein expression in renal tissues. The significant decreases in glutathione content, catalase, superoxide dismutase, glutathione-S-transferase, glutathione peroxidase, and glutathione reductase activities and the increase in malondialdehyde content indicated that GM-induced tissue injury was mediated through oxidative reactions. In contrast, MT treatment protected kidney tissue against the oxidative damage and the nephrotoxic effect caused by the GM treatment. Histopathological studies confirmed the renoprotective effect of MT. These results indicate that MT prevents nephrotoxicity induced by GM in rats, presumably because it is a potent antioxidant, restores antioxidant enzyme activity, and blocks NF-κB and iNOS activation in rat kidney.

Download full-text


Available from: Jong Choon Kim, May 18, 2014
  • Source
    • "Melatonin is involved in many cellular functions, such as inducing cell cycle arrest and apoptosis in HepG2 cells (Martin-Renedo et al., 2008), regulating inflammatory and immune responses, promoting acute inflammation, and preventing chronic inflammation (Radogna et al., 2010). Moreover, melatonin has been shown to protect against the toxic effects of gentamicin in rat kidneys (Lee et al., 2012a), decrease the testicular toxicity of doxorubicin in rats (Lee et al., 2012b), ameliorate the effects of toxic radiation in normal mouse splenocytes (Jang et al., 2009), inhibit toxic rotenone cell injury in HeLa cells (Zhou et al., 2012), and decrease tetrachloride hepatotoxicity in rats (Aranda et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Melatonin, a hormoneknown for its effects onfree radical scavenging and antioxidant activity, can reduce lead toxicity in vivo and in vitro.We examined the effects ofmelatonin on lead bio-distribution. Rats were intraperitoneally injected with lead acetate (10, 15 or 20mg/kg/day) with or without melatonin (10mg/kg/day) daily for 10 days. In rats intoxicated with the highest lead doses, those treated with melatoninhad lower leadlevelsin blood and higher levels in urine and feces than those treated with lead alone, suggesting that melatonin increaseslead excretion. To explore the mechanism underlying this effect, we firstassessed whether lead/melatonin complexes were formed directly. Electronic density functional (DFT) calculations showed that a lead/melatonin complex is energetically feasible; however, UV spectroscopy and NMRanalysis showed noevidence of such complexes. Next, we examined the liver mRNA levels of metallothioneins (MT) 1 and 2. Melatonin cotreatment increased the MT2 mRNA expression in theliver ofrats that received the highest doses of lead. The potential effectsof MTs on the tissue distribution and excretion of lead are not well understood. This is the first report to suggest that melatonindirectlyaffectslead levels in organisms exposed to subacute lead intoxication. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Toxicology Letters 01/2015; 233(2). DOI:10.1016/j.toxlet.2015.01.009 · 3.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Doxorubicin (DOX), a prominent anticancer agent has enjoyed considerable popularity in the last few decades because of its usefulness in the management of various forms of cancers, but its organotoxic potential (cardio-, hepato- and nephrotoxicity) has constrained on its clinical use. This study investigated whether DOX has the ability to cause nephrotoxicity in vivo and if so, whether it is linked to oxidative stress (OS). Another important goal was to unravel whether expression of pro- and anti-apoptotic genes in kidneys were driven by OS. In order to explore DOXs nephrotoxic potential, male rats (Sprague Dawley; 500520g; fed ad libitum) were administered i.p. with a single dose of DOX (12 mg/kg) on day one and sacrificed seven days later (day 8). Changes in serum chemistries (i.e., blood urea nitrogen and creatinine) were determined immediately upon sacrifice, whereas kidney tissues were subjected to several sensitive biomarkers for OS, such as, lipid peroxidation, SOD activity and chromatin fragmentation. The most important goal was to evaluate the select expression of Apaf-1, Caspase-3, Bad, Bax, Bcl-2, Bcl-xL, p53 and Mdm2 genes in order to understand the underlying link between extrinsic and intrinsic pathways of cell death. Data revealed that DOX-exposed animals showed significant nephrotoxicity as reflected in increased SUN (5.6-fold) and creatinine (2.65 fold) levels with considerably decreased body weight. Increases in kidney injury markers reflected parallel elevations in lipid peroxidation (1.7 fold) and genomic DNA fragmentation (2.9 fold) coupled with a proportionate reduction in total SOD activity suggesting DOX-assaulted kidneys encountered massive OS. Western blot showed very striking changes: i) substantial increases in the expression of pro-apoptotic APAF-1, Caspase-3, Bax and Bad proteins; ii) Reduction in the expression of anti-apoptotic Bcl-2 and Bcl-xL genes; iii) considerable increase in the expression of p53 and suppression of its regulator Mdm2. Serum chemistry and tissue biochemistry mirrored histopathology. In conclusion, this study for the first time may have shown a close link between mitochondrial perturbations and cell death regulating genes during DOX-induced nephrotoxicity, and unraveled DOXs potential to inflict kidney injury in addition to other organs during chemotherapy in clinical setting.
    Current neurovascular research 08/2012; 9(4). DOI:10.2174/156720212803530636 · 2.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pineal gland melatonin is the darkness hormone, while extra-pineal melatonin produced by the gonads, gut, retina, and immune competent cells acts as a paracrine or autocrine mediator. The well-known immunomodulatory effect of melatonin is observed either as an endocrine, a paracrine or an autocrine response. In mammals, nuclear translocation of nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) blocks noradrenaline-induced melatonin synthesis in pinealocytes, which induces melatonin synthesis in macrophages. In addition, melatonin reduces NF-κB activation in pinealocytes and immune competent cells. Therefore, pathogen- or danger-associated molecular patterns transiently switch the synthesis of melatonin from pinealocytes to immune competent cells, and as the response progresses melatonin inhibition of NF-κB activity leads these cells to a more quiescent state. The opposite effect of NF-κB in pinealocytes and immune competent cells is due to different NF-κB dimers recruited in each phase of the defense response. This coordinated shift of the source of melatonin driven by NF-κB is called the immune-pineal axis. Finally, we discuss how this concept might be relevant to a better understanding of pathological conditions with impaired melatonin rhythms and hope it opens new horizons for the research of side effects of melatonin-based therapies.
    International Journal of Molecular Sciences 06/2013; 14(6):10979-10997. DOI:10.3390/ijms140610979 · 2.86 Impact Factor
Show more